ArticlePLoS computational biology2017
Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy.
Article in PLoS computational biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Recent advances in interstitial fluid dynamics for diagnostic, targeted drug delivery and precision medicine applications.Drug delivery and translational research · 2026Review
- Lenvatinib Monotherapy Versus Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Osteosarcoma: A Real-World Study.Drug design, development and therapy · 2025Article
- Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization.PLoS computational biology · 2023Article
- Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models.Frontiers in oncology · 2023Article
- Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.Expert review of anticancer therapy · 2022Review
- Numerical Investigation on the Anti-Angiogenic Therapy-Induced Normalization in Solid Tumors.Pharmaceutics · 2022Article
- Chemotherapy response prediction with diffuser elapser network.Scientific reports · 2022Article
- Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals.Science advances · 2022Article
- Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin.Frontiers in molecular biosciences · 2022Article
- Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy.Frontiers in oncology · 2022Review
- Mathematical simulation of tumour angiogenesis: angiopoietin balance is a key factor in vessel growth and regression.Scientific reports · 2021Article
- The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies.Frontiers in oncology · 2021Review
- In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery.PLoS computational biology · 2020Article
- Targeting Fluorescence Imaging of RGD-Modified Indocyanine Green Micelles on Gastric Cancer.Frontiers in bioengineering and biotechnology · 2020Article
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment.Journal of clinical medicine · 2019Review
- Towards microvascular pressure estimation using ultrasound and photoacoustic imaging.Photoacoustics · 2019Article
- Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin.Pharmaceutics · 2019Article
- Nanoparticle Delivery and Tumor Vascular Normalization: The Chicken or The Egg?Frontiers in oncology · 2019Review
- Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues.Journal of the Royal Society, Interface · 2018Review
- An ecosystem framework for understanding and treating disease.Evolution, medicine, and public health · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-induced angiogenesis leads to the development of leaky tumor vessels devoid of structural and morphological integrity. Due to angiogenesis, elevated interstitial fluid pressure (IFP) and low blood perfusion emerge as common properties of the tumor microenvironment that act as barriers for drug delivery. In order to overcome these barriers, normalization of vasculature is considered to be a viable option. However, insight is needed into the phenomenon of normalization and in which conditions it can realize its promise. In order to explore the effect of microenvironmental conditions and drug scheduling on normalization benefit, we build a mathematical model that incorporates tumor growth, angiogenesis and IFP. We administer various theoretical combinations of antiangiogenic agents and cytotoxic nanoparticles through heterogeneous vasculature that displays a similar morphology to tumor vasculature. We observe differences in drug extravasation that depend on the scheduling of combined therapy; for concurrent therapy, total drug extravasation is increased but in adjuvant therapy, drugs can penetrate into deeper regions of tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.